US Stock MarketDetailed Quotes

RPRX Royalty Pharma

Watchlist
  • 31.650
  • +0.090+0.29%
Close Mar 27 16:00 ET
  • 31.650
  • 0.0000.00%
Post 16:34 ET
13.71BMarket Cap16.57P/E (TTM)

About Royalty Pharma Company

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Company Profile

SymbolRPRX
Company NameRoyalty Pharma
Listing DateJun 16, 2020
Issue Price28.00
Founded2020
CEOMr. Pablo Legorreta
MarketNASDAQ
Employees99
Fiscal Year Ends12-31
Address110 East 59th Street,33rd floor
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10022
Phone1-212-883-0200

Company Executives

  • Name
  • Position
  • Salary
  • Pablo Legorreta
  • Chairman of the Board and Chief Executive Officer
  • --
  • George Lloyd
  • Executive Vice President, Investments and Chief Legal Officer
  • 4.56M
  • Terrance Coyne
  • Principal Accounting Officer, Executive Vice President and Chief Financial Officer
  • 4.56M
  • Christopher Hite
  • Executive Vice President and Vice Chairman
  • 4.56M
  • Dr. Marshall Urist, M.D.
  • Executive Vice President, Research and Investments
  • 4.56M
  • Rory B. Riggs
  • Independent Director
  • 318.48K
  • M. Germano Giuliani
  • Independent Director
  • 318.48K
  • Catherine M. Engelbert
  • Independent Director
  • 389.77K
  • Henry A. Fernandez
  • Lead Independent Director
  • 389.77K
  • Gregory Norden
  • Independent Director
  • 389.77K
  • David C. Hodgson
  • Independent Director
  • 389.77K
  • Dr. Ted W. Love, M.D.
  • Independent Director
  • 389.77K
  • Dr. Errol B. De Souza,PhD
  • Independent Director
  • 389.77K
  • Dr. Bonnie L. Bassler, PhD
  • Independent Director
  • 389.77K
Market Insights
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks

Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.